Camblong Jurgi sold $286K of SOPH
Camblong Jurgi (Executive Chairman) sold 44,381 shares of SOPHiA GENETICS SA (SOPH) at an average of $6.45 ($6.17–$6.63, $0.29M total) across 3 trades over 2026-07-20 to 2026-07-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest information is the specific sale size, execution dates, price range, and post-transaction holdings, which can influence short-term sentiment but typically has limited fundamental impact when tied to a 10b5-1 plan.
Market read
This is a routine insider-sale filing with disclosed transaction details; it is more relevant for sentiment monitoring than for a new fundamental thesis.
What to watch
Traders should check for any concurrent insider buys, additional Form 4 filings, or changes in guidance/financing that would make the sale more informative.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by executive chairman Camblong Jurgi.
Ticker impact
SEC Form 4 shows executive chairman Camblong Jurgi sold 44,381 SOPH shares for about $286.1K under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; any price reaction should be small unless accompanied by other disclosures.
The filing is a primary-source insider transaction with disclosed size, pricing range, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single, small insider sale disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than negative expectations.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction disclosure.
- insiderCamblong Jurgi
Executive Chairman who sold shares under a pre-arranged 10b5-1 plan.
